AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD (NCT03989713) | Prof. Dr. Richard F Schlenk | 2020-07-17 |
Track AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment) automatically
Every clearance here is in the API, with alerts when new ones post.